Literature DB >> 18263964

Aberrant epigenetic patterns in the etiology of gastrointestinal cancers.

Paweł Karpiński1, Maria M Sasiadek, Nikolaus Blin.   

Abstract

A body of evidence accumulated over the past decade suggests that epigenetic mechanisms play an essential role in maintaining important cellular functions. Changes in epigenetic patterns (mainly DNA hyper- and hypomethylation and, more recently, histone modifications) may contribute to the development of cancer. Aberrant epigenetic events expand thorough tumor progression from the earliest to latest stages, therefore they can serve as convenient markers for detection and prognosis of cancer. The potential reversibility of epigenetic states in the tumor cell is an attractive target for cancer therapy. Much of our current knowledge on epigenetic alternations in cancer comes from studies on gastrointestinal malignancies, mainly on colorectal cancer, which currently serves as a model for epigenetic tumorigenesis. This review summarizes the current knowledge of epigenetic changes in gastrointestinal cancers and how this relates directly to disease progression and prognosis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18263964     DOI: 10.1007/BF03195243

Source DB:  PubMed          Journal:  J Appl Genet        ISSN: 1234-1983            Impact factor:   2.653


  86 in total

Review 1.  Molecular evolution of the metaplasia-dysplasia-adenocarcinoma sequence in the esophagus.

Authors:  J A Jankowski; N A Wright; S J Meltzer; G Triadafilopoulos; K Geboes; A G Casson; D Kerr; L S Young
Journal:  Am J Pathol       Date:  1999-04       Impact factor: 4.307

2.  CpG island methylation in premalignant stages of gastric carcinoma.

Authors:  G H Kang; Y H Shim; H Y Jung; W H Kim; J Y Ro; M G Rhyu
Journal:  Cancer Res       Date:  2001-04-01       Impact factor: 12.701

3.  Correlation of pathologic features with CpG island methylator phenotype (CIMP) by quantitative DNA methylation analysis in colorectal carcinoma.

Authors:  Shuji Ogino; Robert D Odze; Takako Kawasaki; Mohan Brahmandam; Gregory J Kirkner; Peter W Laird; Massimo Loda; Charles S Fuchs
Journal:  Am J Surg Pathol       Date:  2006-09       Impact factor: 6.394

4.  CpG island methylation status in gastric carcinoma with and without infection of Epstein-Barr virus.

Authors:  Moon-Sung Chang; Hiroshi Uozaki; Ja-Mun Chong; Tetsuo Ushiku; Kazuya Sakuma; Shunpei Ishikawa; Rumi Hino; Rita Rani Barua; Yoshiaki Iwasaki; Kuniyoshi Arai; Hideki Fujii; Hideo Nagai; Masashi Fukayama
Journal:  Clin Cancer Res       Date:  2006-05-15       Impact factor: 12.531

5.  Aberrant methylation of the Cyclooxygenase 2 CpG island in colorectal tumors.

Authors:  M Toyota; L Shen; M Ohe-Toyota; S R Hamilton; F A Sinicrope; J P Issa
Journal:  Cancer Res       Date:  2000-08-01       Impact factor: 12.701

6.  Differential DNA hypermethylation and hypomethylation signatures in colorectal cancer.

Authors:  Jordi Frigola; Xavier Solé; Maria F Paz; Victor Moreno; Manel Esteller; Gabriel Capellà; Miguel A Peinado
Journal:  Hum Mol Genet       Date:  2004-12-01       Impact factor: 6.150

7.  DNA methylation of multiple genes in gastric carcinoma: association with histological type and CpG island methylator phenotype.

Authors:  Naohide Oue; Yasuhiro Oshimo; Hirofumi Nakayama; Reiko Ito; Kazuhiro Yoshida; Keisuke Matsusaki; Wataru Yasui
Journal:  Cancer Sci       Date:  2003-10       Impact factor: 6.716

8.  Aberrant promoter methylation of p16 and MGMT genes in lung tumors from smoking and never-smoking lung cancer patients.

Authors:  Yang Liu; Qing Lan; Jill M Siegfried; James D Luketich; Phouthone Keohavong
Journal:  Neoplasia       Date:  2006-01       Impact factor: 5.715

9.  Hypomethylation of L1 retrotransposons in colorectal cancer and adjacent normal tissue.

Authors:  Catherine M Suter; David I Martin; Robyn L Ward
Journal:  Int J Colorectal Dis       Date:  2003-10-08       Impact factor: 2.571

10.  Promoter methylation of cyclin D2 gene in gastric carcinoma.

Authors:  Yasuhiro Oshimo; Hirofumi Nakayama; Reiko Ito; Yasuhiko Kitadai; Kazuhiro Yoshida; Kazuaki Chayama; Wataru Yasui
Journal:  Int J Oncol       Date:  2003-12       Impact factor: 5.650

View more
  13 in total

1.  Methylated DNA immunoprecipitation.

Authors:  Kelsie L Thu; Emily A Vucic; Jennifer Y Kennett; Cameron Heryet; Carolyn J Brown; Wan L Lam; Ian M Wilson
Journal:  J Vis Exp       Date:  2009       Impact factor: 1.355

2.  Drug resistance induces the upregulation of H2S-producing enzymes in HCT116 colon cancer cells.

Authors:  Ashley A Untereiner; Athanasia Pavlidou; Nadiya Druzhyna; Andreas Papapetropoulos; Mark R Hellmich; Csaba Szabo
Journal:  Biochem Pharmacol       Date:  2017-10-20       Impact factor: 5.858

3.  Oridonin induces apoptosis and senescence in colorectal cancer cells by increasing histone hyperacetylation and regulation of p16, p21, p27 and c-myc.

Authors:  Feng-Hou Gao; Xiao-Hui Hu; Wei Li; Hua Liu; Yan-Jie Zhang; Zhu-Ying Guo; Mang-Hua Xu; Shi-Ting Wang; Bin Jiang; Feng Liu; Ying-Zheng Zhao; Yong Fang; Fang-Yuan Chen; Ying-Li Wu
Journal:  BMC Cancer       Date:  2010-11-06       Impact factor: 4.430

4.  The blues of P(16)INK(4a): aberrant promoter methylation and association with colorectal cancer in the Kashmir valley.

Authors:  A Syed Sameer; Safiya Abdullah; Saniya Nissar; Roohi Rasool; Zaffar A Shah; Dil Afroze; Nissar A Chowdri; Mushtaq A Siddiqi
Journal:  Mol Med Rep       Date:  2012-01-03       Impact factor: 2.952

5.  Analysis of molecular aberrations of Wnt pathway gladiators in colorectal cancer in the Kashmiri population.

Authors:  A Syed Sameer; Zaffar A Shah; Safiya Abdullah; Nissar A Chowdri; Mushtaq A Siddiqi
Journal:  Hum Genomics       Date:  2011-07       Impact factor: 4.639

6.  Detection of viral DNA sequences in sporadic colorectal cancers in relation to CpG island methylation and methylator phenotype.

Authors:  Pawel Karpinski; Aleksander Myszka; David Ramsey; Wojciech Kielan; Maria Malgorzata Sasiadek
Journal:  Tumour Biol       Date:  2011-04-06

7.  Use of metformin alone is not associated with survival outcomes of colorectal cancer cell but AMPK activator AICAR sensitizes anticancer effect of 5-fluorouracil through AMPK activation.

Authors:  Xinbing Sui; Yinghua Xu; Jie Yang; Yong Fang; Haizhou Lou; Weidong Han; Maolin Zhang; Wei Chen; Kaifeng Wang; Da Li; Wei Jin; Fang Lou; Yu Zheng; Hong Hu; Liu Gong; Xiaoyun Zhou; Qin Pan; Hongming Pan; Xian Wang; Chao He
Journal:  PLoS One       Date:  2014-05-21       Impact factor: 3.240

8.  Stratified randomization controls better for batch effects in 450K methylation analysis: a cautionary tale.

Authors:  Olive D Buhule; Ryan L Minster; Nicola L Hawley; Mario Medvedovic; Guangyun Sun; Satupaitea Viali; Ranjan Deka; Stephen T McGarvey; Daniel E Weeks
Journal:  Front Genet       Date:  2014-10-13       Impact factor: 4.599

9.  Qualitative analysis of Adenomatous Polyposis Coli promoter: hypermethylation, engagement and effects on survival of patients with esophageal cancer in a high risk region of the world, a potential molecular marker.

Authors:  Maryam Zare; Ferdous Rastgar Jazii; Mohammad Reza Alivand; Negin Karimi Nasseri; Reza Malekzadeh; Mansour Yazdanbod
Journal:  BMC Cancer       Date:  2009-01-17       Impact factor: 4.430

10.  JNK confers 5-fluorouracil resistance in p53-deficient and mutant p53-expressing colon cancer cells by inducing survival autophagy.

Authors:  Xinbing Sui; Na Kong; Xian Wang; Yong Fang; Xiaotong Hu; Yinghua Xu; Wei Chen; Kaifeng Wang; Da Li; Wei Jin; Fang Lou; Yu Zheng; Hong Hu; Liu Gong; Xiaoyun Zhou; Hongming Pan; Weidong Han
Journal:  Sci Rep       Date:  2014-04-15       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.